Cargando…

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis

BACKGROUND AND OBJECTIVE: The concentration of neurofilament light (NfL) protein in cerebrospinal fluid (CSF) and blood is widely considered as a quantitative measure of neuro-axonal injury. Immune reactivity to NfL released into extracellular fluids induces specific autoantibody response. We invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puentes, Fabiola, Benkert, Pascal, Amor, Sandra, Kuhle, Jens, Giovannoni, Gavin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587694/ https://www.ncbi.nlm.nih.gov/pubmed/34786556 http://dx.doi.org/10.1136/bmjno-2021-000192

Ejemplares similares

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
por: Lu, Ching-Hua, et al.
Publicado: (2015)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
por: Saak, Annika, et al.
Publicado: (2021)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Decreased neurofilament light chain levels in estriol‐treated multiple sclerosis
por: Voskuhl, Rhonda, et al.
Publicado: (2022)

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
por: Hermesdorf, Marco, et al.
Publicado: (2022)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Development of an age‐adjusted model for blood neurofilament light chain
por: Harp, Christopher, et al.
Publicado: (2022)

The Evolution of Neurofilament Light Chain in Multiple Sclerosis
por: Ferreira-Atuesta, Carolina, et al.
Publicado: (2021)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Factors influencing serum neurofilament light chain levels in normal aging
por: Koini, Marisa, et al.
Publicado: (2021)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
por: Maggi, Pietro, et al.
Publicado: (2021)

Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis
por: Lin, Ting-Yi, et al.
Publicado: (2021)

Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis
por: Kouchaki, Ebrahim, et al.
Publicado: (2021)

Serum neurofilament light levels in normal aging and their association with morphologic brain changes
por: Khalil, Michael, et al.
Publicado: (2020)

Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study
por: Rübsamen, Nicole, et al.
Publicado: (2021)

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury
por: Depoorter, Antoinette, et al.
Publicado: (2018)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4
por: Kessler, Christoph, et al.
Publicado: (2022)

Kynurenines and Neurofilament Light Chain in Multiple Sclerosis
por: Pukoli, Dániel, et al.
Publicado: (2021)

Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates
por: Polymeris, Alexandros A, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
por: Gaiottino, Johanna, et al.
Publicado: (2013)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis
por: Puentes, Fabiola, et al.
Publicado: (2013)

The Refinement of Genetic Predictors of Multiple Sclerosis
por: Disanto, Giulio, et al.
Publicado: (2014)

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
por: Yeo, Tianrong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h5g3vuvh5rj80u0g8ltq7d7qc9